TL;DR
This study identifies Non-POU-domain-containing octamer-binding protein (NONO) as a key player in the development of abdominal aortic aneurysms (AAAs). By silencing NONO in a mouse model, researchers significantly reduced AAA formation and severity, suggesting NONO as a potential therapeutic target for this life-threatening condition.
What Problem Does This Paper Address?
Abdominal aortic aneurysms (AAAs) are a serious vascular disease characterized by the dangerous enlargement of the aorta. Despite their high mortality rate, effective medical treatments are limited, making the identification of new therapeutic targets crucial. While the role of inflammation and extracellular matrix remodeling in AAA pathogenesis is recognized, the specific molecular mechanisms driving these processes are not fully understood. This paper investigates the involvement of NONO, a protein known for its roles in gene regulation, in the development of Angiotensin II (Ang II)-induced AAAs in apolipoprotein E-knockout (ApoE<sup>-/-</sup>) mice.
Methods
The researchers employed a multi-pronged approach using a mouse model of AAA and cultured vascular smooth muscle cells (VSMCs).
- Animal Model: ApoE<sup>-/-</sup> mice were used, a standard model for studying atherosclerosis and AAA. Angiotensin II (Ang II) was infused subcutaneously to induce AAA formation.
- NONO Silencing: Lentiviral vectors carrying short hairpin RNA (shRNA) targeting NONO (sh-NONO) were used to reduce NONO expression in vivo and in vitro. Control groups received either no treatment, Ang II alone, or Ang II with a scrambled shRNA (sh-NC).
- Histopathology and Immunohistochemistry: Aortic tissues were analyzed using various staining techniques (H&E, Verhoff, Masson, Sirius Red) to assess structural changes, elastic fiber integrity, collagen content, and smooth muscle cell presence. Immunohistochemistry was used to quantify macrophage infiltration (CD68), and the expression of key proteins like collagen I, collagen III, prolyl-4-hydroxylase α1 (P4Hx1), and matrix metalloproteinases (MMPs).
- Western Blotting: Protein levels of NONO, collagen I, collagen III, P4Hx1, MMP2, MMP9, and inflammatory cytokines (IL-1β, MCP-1, IL-6, TNF-α) were measured.
- Co-immunoprecipitation and Immunofluorescence: These techniques were used to investigate the interaction between NONO and NF-κB p65, and to assess NF-κB p65's nuclear translocation and phosphorylation.
- In Vitro Studies: VSMCs were stimulated with Ang II and treated with sh-NONO lentivirus to examine the effects of NONO knockdown on cellular processes.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- NONO is Upregulated in AAA: The study found that NONO protein levels were significantly higher in AAA tissues compared to normal aortas, and also increased in Ang II-stimulated VSMCs. This suggests NONO plays a role in AAA development.
- NONO Silencing Protects Against AAA: Reducing NONO levels in ApoE<sup>-/-</sup> mice treated with Ang II markedly decreased the incidence and severity of AAAs, as well as reduced aortic diameter.
- NONO Modulates ECM Remodeling: Silencing NONO led to increased collagen deposition (indicated by Sirius Red staining and increased collagen I, III, and P4Hx1 expression) and decreased collagen degradation (reduced MMP2 and MMP9 activity). This points to NONO's role in regulating the balance of extracellular matrix in the aortic wall.
- NONO Inhibits Inflammation: NONO knockdown significantly reduced the infiltration of macrophages and the expression of pro-inflammatory cytokines (IL-1β, MCP-1, IL-6, TNF-α) in AAA tissues and VSMCs.
- NONO Interacts with NF-κB: The research revealed that NONO directly interacts with NF-κB p65. Silencing NONO inhibited the nuclear translocation and phosphorylation of NF-κB p65, a key transcription factor involved in inflammation. This suggests a critical mechanistic link between NONO and inflammatory pathways in AAA.
Key Results
- NONO expression was approximately 1.5-fold higher in AAA tissues compared to controls.
- NONO knockdown reduced AAA incidence by approximately 40% (from 84% in sh-NC to 48% in sh-NONO groups).
- Maximal abdominal aortic diameters were significantly reduced in NONO-silenced mice.
- Collagen deposition (Sirius Red staining) increased by over 3-fold in sh-NONO treated mice compared to controls.
- Expression of pro-inflammatory cytokines like IL-1β was reduced by approximately 50% in sh-NONO treated mice.
- NONO silencing suppressed NF-κB p65 phosphorylation by about 55%.
Limitations and Future Work
- Model Specificity: While the ApoE<sup>-/-</sup> mouse model with Ang II infusion is well-established, its direct translation to human AAA pathogenesis requires further investigation.
- Mechanism Nuances: While the interaction with NF-κB is identified, further research could explore the precise molecular cascade through which NONO influences NF-κB signaling and downstream inflammatory and ECM remodeling pathways.
- Therapeutic Potential: The study strongly suggests NONO as a therapeutic target. Future work could focus on developing specific NONO inhibitors or exploring alternative delivery methods for gene silencing in a clinical setting. The authors also mention that NONO knockdown did not affect lipid levels or blood pressure, indicating its specific role in AAA pathogenesis rather than general cardiovascular risk factors.
Summary updated